Finnish Police Find Synthetic Marijuana in Underage E-cigarettes

Aug.06.2024
Finnish Police Find Synthetic Marijuana in Underage E-cigarettes
Finnish police discovered underage individuals with e-cigarettes containing synthetic cannabis, raising concerns about illegal imports and health risks.

According to a report by Pledge Times on August 5th, Finnish police have discovered some minors in possession of e-cigarettes or vaporizers containing synthetic cannabinoids. This is the first case in Finland where such drugs have been found in confiscated e-cigarettes.


Tuomas Puukko, the chief of the Finnish Häme Police Department, expressed his belief that there may be more similar e-cigarettes on the market. In a recent case, authorities investigated suspicious packaging labels. In the future, the police will pay more attention to inspecting e-cigarette packaging, but the complexity of supervision lies in the fact that underage individuals rarely carry these e-cigarette packages.


Local police consider e-cigarettes containing synthetic cannabinoids to be illegally imported. A press release from the Hamay Police Department stated that the use of e-cigarettes among young people has been increasing, causing concern for law enforcement. According to a study, it is estimated that e-cigarette use is more common among young people than smoking traditional cigarettes. Police observation indicates that the youngest e-cigarette users are around 12 to 13 years old.


Public Health Agency pointed out that even regular e-cigarette use carries many health risks. The Finnish Institute for Health and Welfare (THL) stated that using e-cigarettes can harm lung function, expose people to various harmful substances, and increase the risk of cardiovascular and respiratory diseases. THL also explained that synthetic cannabinoids are a type of designer drug, with effects and structures similar to traditional drugs, but with even higher risks. Synthetic cannabinoids are stronger than natural marijuana, making dose control difficult.


We welcome news tips, article submissions, interview requests, or comments on this piece.

Please contact us at info@2firsts.com, or reach out to Alan Zhao, CEO of 2Firsts, on LinkedIn


Notice

1.  This article is intended solely for professional research purposes related to industry, technology, and policy. Any references to brands or products are made purely for objective description and do not constitute any form of endorsement, recommendation, or promotion by 2Firsts.

2.  The use of nicotine-containing products — including, but not limited to, cigarettes, e-cigarettes, nicotine pouchand heated tobacco products — carries significant health risks. Users are responsible for complying with all applicable laws and regulations in their respective jurisdictions.

3.  This article is not intended to serve as the basis for any investment decisions or financial advice. 2Firsts assumes no direct or indirect liability for any inaccuracies or errors in the content.

4.  Access to this article is strictly prohibited for individuals below the legal age in their jurisdiction.

 

Copyright

 

This article is either an original work created by 2Firsts or a reproduction from third-party sources with proper attribution. All copyrights and usage rights belong to 2Firsts or the original content provider. Unauthorized reproduction, distribution, or any other form of unauthorized use by any individual or organization is strictly prohibited. Violators will be held legally accountable.

For copyright-related inquiries, please contact: info@2firsts.com

 

AI Assistance Disclaimer

 

This article may have been enhanced using AI tools to improve translation and editorial efficiency. However, due to technical limitations, inaccuracies may occur. Readers are encouraged to refer to the cited sources for the most accurate information.

We welcome any corrections or feedback. Please contact us at: info@2firsts.com

FDA PMTA Roundtable: Ongoing Comprehensive Coverage by 2Firsts
FDA PMTA Roundtable: Ongoing Comprehensive Coverage by 2Firsts
Feb.11
Coalition pushes back on Hochul’s proposed 75% wholesale tax on alternative nicotine products
Coalition pushes back on Hochul’s proposed 75% wholesale tax on alternative nicotine products
A coalition of business owners and former law enforcement officers protested Gov. Kathy Hochul’s proposed 75% wholesale tax on alternative nicotine products, saying it would fuel organized crime and burden low-income New Yorkers, while supporters said it would curb addiction and help fund hospitals.
Feb.28 by 2FIRSTS.ai
Azerbaijan parliament passes third-reading amendments introducing e-cigarette penalties, effective April 1, 2026
Azerbaijan parliament passes third-reading amendments introducing e-cigarette penalties, effective April 1, 2026
Azerbaijan’s Milli Majlis has adopted, in its third reading, amendments to the Code of Administrative Offences introducing fines and confiscation for the use of e-cigarettes and their components, as well as import, export, production, wholesale and retail sales, and storage for sale.
Mar.04 by 2FIRSTS.ai
BAT CEO: to ramp up ‘next-generation’ tobacco capacity in Italy, plans €500 mln investment in Trieste plant by 2027
BAT CEO: to ramp up ‘next-generation’ tobacco capacity in Italy, plans €500 mln investment in Trieste plant by 2027
British American Tobacco (BAT) CEO Tadeu Marroco said the group will continue to invest in equipment and technology in Italy and expand capacity for next-generation tobacco products such as e-cigarettes and heated tobacco. BAT’s Trieste innovation hub is slated to receive a total investment of 500 million euros by 2027 and add 16 new production lines.
Feb.03 by 2FIRSTS.ai
New Zealand Vape Company Alt Becomes Government Partner After Suing Over Nicotine Limits
New Zealand Vape Company Alt Becomes Government Partner After Suing Over Nicotine Limits
Health NZ signed a NZD 500,000 contract with New Zealand-owned vape company Alt NZ Limited in December 2025 for its free vape kit programme for smokers, with more than 7,000 kits distributed so far.
Mar.23 by 2FIRSTS.ai
Rethinking Nicotine Harm Reduction: A Neuroscientist’s Perspective on Scientific Gaps and Future Directions — By Dr. Xin-an Liu
Rethinking Nicotine Harm Reduction: A Neuroscientist’s Perspective on Scientific Gaps and Future Directions — By Dr. Xin-an Liu
After France’s ANSES report on nicotine products and harm reduction, Dr. Xin-an Liu wrote to 2Firsts reassessing the field’s foundations. She argues the debate reveals gaps in evidence on long-term behavioral substitution, addiction pathways and neurobiological impacts, and calls for longitudinal research, integrated behavioral science and neuroimaging, clearer risk assessment and stronger transparency to ensure policy and next-generation product development rest on solid evidence.
Industry Insight
Feb.24